Trial Search Results

Closed-loop Optimized rTMS for Depression

Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional brain networks in those with mental illness. rTMS is FDA-approved for depression and obsessive-compulsive disorder with clinical trials underway for PTSD and addiction, among others. However, remission rates are suboptimal and ideal stimulation parameters are unknown. I recently completed a randomized, double blind clinical trial and a depression severity biomarker that predicts clinical outcome. The overarching goal of this study is to develop the first broadly generalizable platform for real-time biomarker monitoring and personalized rTMS treatment. I plan to recruit patients with medication-resistant depression and in perform a four-phase, cross-over, double-blind, placebo-controlled trial to 1) identify how standard and optimized rTMS patterns engage the depression severity biomarker, and 2) determine the dose-response of these rTMS patterns. Findings from this study will provide the basis for a double-blind, randomized clinical trial comparing rTMS optimized to the individual against standard rTMS.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Device: closed-loop rTMS
  • Device: open-loop rTMS
  • Device: sham rTMS




Inclusion Criteria:

   - Men and women, ages 18 to 65

   - Depression assessed through phone screen

   - Not currently on antidepressant medications

   - Must comprehend English well to ensure adequate comprehension of the EEG and TMS
   instructions, and of clinical scales

   - Right-handed

   - No current or history of neurological disorders

   - No seizure disorder or risk of seizures

   - No use of PRN medication within 48 hours of the scheduled study appointment

Exclusion Criteria:

   - Those with a contraindication for MRIs (e.g. implanted metal)

   - Any unstable medical condition

   - History of head trauma with loss of consciousness

   - History of seizures

   - Neurological or uncontrolled medical disease

   - Active substance abuse

   - Diagnosis of psychotic or bipolar disorder

   - A prior history of ECT or rTMS failure

   - Currently taking medications that substantially reduce seizure threshold (e.g.,
   olanzapine, chlorpromazine, lithium)

   - Currently pregnant or breastfeeding

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Corey Keller, MD, PhD
(650) 498-9111
Not Recruiting